Sign in
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Journal article   Open access  Peer reviewed

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin, …
The New England journal of medicine, Vol.377(26), pp.2531-2544
2017-12-28
PMCID: PMC5882485
PMID: 29226797

Abstract

Immunotherapy, Adoptive Interleukins - blood Humans Middle Aged Receptors, Antigen, T-Cell - therapeutic use Male Survival Rate Biomarkers - blood T-Lymphocytes - transplantation Lymphoma, Large B-Cell, Diffuse - mortality Young Adult Disease-Free Survival Lymphoma, Large B-Cell, Diffuse - therapy Receptors, Antigen, T-Cell - blood Adult Antigens, CD19 Female Nervous System Diseases - chemically induced T-Lymphocytes - immunology Aged Neutropenia - chemically induced
url
https://doi.org/10.1056/NEJMoa1707447View
Published (Version of record) Open

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Highly Cited Paper 
Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.6 Immunology
1.6.214 PD-1
Web Of Science research areas
Hematology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details